Plain-English translation of NCT04943913 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a treatment called GC101 TIL, which uses your own immune cells to fight brain glioma. Doctors remove immune cells that have naturally gathered in your tumor during surgery, grow many more copies of them in the laboratory, and then infuse them back into your bloodstream. The goal is to see if this medication can safely slow or stop your cancer from growing.
Standard treatments like chemotherapy and radiation don't work well enough for everyone with malignant brain glioma, especially when the cancer returns or spreads. This trial explores whether using your own immune system—specifically cells already primed to recognize and fight your cancer—might offer a new hope for patients whose tumors have not responded to existing treatments.
You likely qualify if…
You likely don't qualify if…
First, you would undergo surgery or a biopsy to remove tumor tissue so doctors can extract immune cells from it. These cells are then grown in large numbers in the laboratory over several weeks. Before receiving the treatment, you will receive two medications to temporarily weaken your immune system to make room for the new cells. Finally, the expanded immune cells are infused back into your bloodstream through an IV. You would then be monitored closely with follow-up visits to check for safety and how well the treatment is working.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Shanghai Juncell Therapeutics
Collaborators
Second Affiliated Hospital of Soochow University
Enrollment target
~50 participants
Started
May 2021
Primary completion
December 2026
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
GC Clinical
Second Affiliated Hospital of Soochow University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.